Skip to main content
Premium Trial:

Request an Annual Quote

Singapore's National University Cancer Institute, HealthSeq Asia Partner to Study AML Genomes

NEW YORK (GenomeWeb) – The National University Cancer Institute, Singapore and HealthSeq Asia will collaborate on a research project to sequence 150 acute myeloid leukemia genomes to better understand the disease in Asian populations.

HealthSeq, a health technology company that is building data clouds for genomic information, will perform the sequencing through its partner Tempus Labs. The data will then be analyzed on a data cloud developed by HealthSeq and the National University Hospital of Singapore.

In the study, the researchers will focus on analyzing the genomes of AML patients who are exceptional responders as well as refractory patients and will compare the genomes to matched controls. They will analyze both genomic and transcriptomic data as well as clinical data.

"We are excited to expand our collaboration with the NCIS to provide cutting-edge genomic analysis in support of their precision medicine initiatives," HealthSeq Founder and Tempus Labs President Kevin White said in a statement.

"This new study is aimed at continuing to build our capabilities at [the National University Health System] to better understand the underlying causes of diseases relevant to our population," Tai E Shyong, a senior consultant in the division of endocrinology at NUH, said in a statement.